Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone - PubMed (original) (raw)
Clinical Trial
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
Y Miyazaki et al. Diabetes Care. 2001 Apr.
Abstract
Objective: To elucidate the effects of pioglitazone treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Research design and methods: A total of 23 diabetic patients (age 30-70 years BMI < 36 kg/m2) who being treated with a stable dose of sulfonylurea were randomly assigned to receive either placebo (n = 11) or pioglitazone (45 mg/day) (n = 12) for 16 weeks. Before and after 16 weeks of treatment, all subjects received a 75-g oral glucose tolerance test (OGTT) and hepatic peripheral insulin sensitivity was measured with a two-step euglycemic insulin (40 and 160 mU x min(-1) x m(-2) clamp performed with 3-[3H]glucose and indirect calorimetry HbA1c measured monthly throughout the study period.
Results: After 16 weeks of pioglitazone treatment, the fasting plasma glucose (FPG; 184 +/- 15 to 135 +/- 11 mg/dl, P < 0.01), mean plasma glucose during OGTT(293 +/- 12 to 225 +/- 14 mg/dl, P < 0.01), and HbA1c (8.9 +/- 0.3 to 7.2 +/- 0.5%, P < 0.01 ) decreased significantly without change in fasting or glucose-stimulated insulin/C-peptide concentrations. Fasting plasma free fatty acid (FFA; 647 +/- 39 to 478 +/- 49) microEq/l, P < 0.01) and mean plasma FFA during OGTT (485 +/- 30 to 347 +/- 33 microEq/l, P < 0.01) decreased significantly after pioglitazone treatment. Before and after pioglitazone treatment, basal endogenous glucose prodution (EGP) and FPG were strongly correlated (r = 0.67, P < 0.01). EGP during the first insulin clamp step was significantly decreased after pioglitazone treatment (P < 0.05) whereas insulin-stimulated total and nonoxidative glucose disposal during the second insulin clamp was increased (P < 0.01). The change in FPG was related to the change in basal EGP, EGP during the first insulin clamp step, and total glucose disposal during the second insulin clamp step. The change in mean plasma glucose concentration during the OGGTT was strongly related to the change in total body glucose disposl during the second insulin clamp step.
Conclusions: These results suggest that pioglitazone therapy in type 2 diabetic patients decreases lasting and postprandial plasma glucose levels by improving hepatic and peripheral (muscle) tissue sensitivity to insulin.
Similar articles
- Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91. doi: 10.1210/jcem.87.6.8567. J Clin Endocrinol Metab. 2002. PMID: 12050251 - Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
Miyazaki Y, Matsuda M, DeFronzo RA. Miyazaki Y, et al. Diabetes Care. 2002 Mar;25(3):517-23. doi: 10.2337/diacare.25.3.517. Diabetes Care. 2002. PMID: 11874940 Clinical Trial. - Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA. Bajaj M, et al. Diabetes. 2003 Jun;52(6):1364-70. doi: 10.2337/diabetes.52.6.1364. Diabetes. 2003. PMID: 12765945 - [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Ohmura E, Hosaka D, Imai Y, Kawazu S. Ohmura E, et al. Nihon Rinsho. 2002 Sep;60 Suppl 9:470-5. Nihon Rinsho. 2002. PMID: 12387036 Review. Japanese. No abstract available. - Actos (pioglitazone): a new treatment for type 2 diabetes.
Lawrence JM, Reckless JP. Lawrence JM, et al. Hosp Med. 2001 Jul;62(7):411-6. doi: 10.12968/hosp.2001.62.7.1611. Hosp Med. 2001. PMID: 11480129 Review.
Cited by
- Pancreatic beta-cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes.
Moon JH, Choe HJ, Lim S. Moon JH, et al. J Diabetes Investig. 2024 Jun;15(6):669-683. doi: 10.1111/jdi.14221. Epub 2024 Apr 27. J Diabetes Investig. 2024. PMID: 38676410 Free PMC article. Review. - Etiology of Drug-Induced Edema: A Review of Dihydropyridine, Thiazolidinedione, and Other Medications Causing Edema.
Sinnathamby ES, Urban BT, Clark RA, Roberts LT, De Witt AJ, Wenger DM, Mouhaffel A, Willett O, Ahmadzadeh S, Shekoohi S, Kaye AD, Varrassi G. Sinnathamby ES, et al. Cureus. 2024 Feb 1;16(2):e53400. doi: 10.7759/cureus.53400. eCollection 2024 Feb. Cureus. 2024. PMID: 38435190 Free PMC article. Review. - Progression to Obesity: Variations in Patterns of Metabolic Fluxes, Fat Accumulation, and Gastrointestinal Responses.
Milhem F, Komarnytsky S. Milhem F, et al. Metabolites. 2023 Sep 15;13(9):1016. doi: 10.3390/metabo13091016. Metabolites. 2023. PMID: 37755296 Free PMC article. Review. - Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer - A Real-Life Experience.
Percik R, Oedegaard Smith C, Leibovici A, Shai A. Percik R, et al. Biologics. 2023 May 3;17:61-67. doi: 10.2147/BTT.S395817. eCollection 2023. Biologics. 2023. PMID: 37163178 Free PMC article. - Assessment of Efficacy and Safety Using PPAR-γ Agonist-Loaded Nanocarriers for Inflammatory Eye Diseases.
Miralles E, Kamma-Lorger CS, Domènech Ò, Sosa L, Casals I, Calpena AC, Silva-Abreu M. Miralles E, et al. Int J Mol Sci. 2022 Sep 23;23(19):11184. doi: 10.3390/ijms231911184. Int J Mol Sci. 2022. PMID: 36232486 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous